Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

Immunology and Infection

Your institution must subscribe to JoVE's Immunology and Infection section to access this content.

Fill out the form below to receive a free trial or learn more about access:

 

Summary

Here, we describe a method for simultaneous quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs). The TREC/KREC assay can be used as marker of thymic and bone marrow output.

Cite this Article

Copy Citation | Download Citations

Sottini, A., Serana, F., Bertoli, D., Chiarini, M., Valotti, M., Vaglio Tessitore, M., Imberti, L. Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR. J. Vis. Exp. (94), e52184, doi:10.3791/52184 (2014).

Abstract

T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) are circularized DNA elements formed during recombination process that creates T- and B-cell receptors. Because TRECs and KRECs are unable to replicate, they are diluted after each cell division, and therefore persist in the cell. Their quantity in peripheral blood can be considered as an estimation of thymic and bone marrow output. By combining well established and commonly used TREC assay with a modified version of KREC assay, we have developed a duplex quantitative real-time PCR that allows quantification of both newly-produced T and B lymphocytes in a single assay. The number of TRECs and KRECs are obtained using a standard curve prepared by serially diluting TREC and KREC signal joints cloned in a bacterial plasmid, together with a fragment of T-cell receptor alpha constant gene that serves as reference gene. Results are reported as number of TRECs and KRECs/106 cells or per ml of blood. The quantification of these DNA fragments have been proven useful for monitoring immune reconstitution following bone marrow transplantation in both children and adults, for improved characterization of immune deficiencies, or for better understanding of certain immunomodulating drug activity.

Introduction

T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) are small circularized DNA elements that are excised in a proportion of T- and B-cells, respectively, during a genomic DNA recombination process, leading to the formation of a highly diversified repertoire of T- and B-cell receptors. They have no function, but because they are stable and cannot be replicated, they are diluted after each cell division, thus persisting only in one of the two daughter cells. Therefore, their levels in the peripheral blood can be assumed as an estimate of the thymic and bone marrow output.

While the TREC assay has been largely used over the last 15 years to evaluate the extent of thymic output,1 the KREC assay, which was initially developed to measure B-cell proliferation and its contribution to B-cell homeostasis in health and disease,2 has been only recently proposed as a marker of bone marrow output.3,4 Here, we describe the method we developed for the simultaneous quantification of both TRECs and KRECs.4

With this combined method, the variability associated to DNA quantification by real-time PCR is eliminated by the use of a unique standard curve obtained by diluting a triple-insert plasmid containing fragments of TRECs, KRECs and T-cell receptor alpha constant (TCRAC) gene in a 1:1:1 ratio. This allows a more accurate evaluation of the TREC and KREC copy number. Furthermore, the simultaneous quantification of the two targets in the same reaction allows reagent cost reduction.

The proposed TREC/KREC assay can be useful to measure the extent of T- and B-cell neo-production in children or adults with Severe Combined Immunodeficiency (SCID),4 Common Variable Immunodeficiency,5 autoimmune diseases,6-8 and HIV infection.9 Furthermore, it can be used to monitor the immune recovery after hematopoietic stem cell transplantation,10 enzyme replacement,11 and antiviral9 or immunomodulating therapies.6-8 Finally, because SCID patients are recognized using TREC assay despite the underlying genetic defects, and agammaglobulinemia patients can be identified using KREC quantification, the TREC/KREC assay can be also used to detect immunodeficiencies in newborn screening programs.12 In this case, the test must be performed on DNA extracted from small spots of blood blotted and dried on filter paper, must be highly sensitive and specific for the target diseases, as well as highly reproducible and cost-effective.

The introduction of KREC quantification in the test should improve performances of newborn screening for immunodeficiencies, which has routinely been performed in the some parts of the USA (WI, MA, CA) since 2008 when Wisconsin became the first to introduce the analysis of TRECs in its postnatal screening program.13

Subscription Required. Please recommend JoVE to your librarian.

Protocol

NOTE: Ethics statement: This protocol follows the guidelines of our institution, the Spedali Civili di Brescia

1. Preparation of a “Triple-Insert” Plasmid

  1. Selection and preparation of appropriate starting material:
    1. Obtain a sample containing cells very likely to have TRECs and KRECs detectable by PCR, such as peripheral blood of a young healthy subject collected into EDTA tubes.
      NOTE: Originally, we had developed the method using thymocytes for TRECs and mononuclear cells from tonsil fragments for KRECs, but healthy subjects usually have an amount of TRECs and KRECs sufficient to allow their detection by PCR. Therefore, peripheral blood should be a valid alternative, easier to obtain and to work with. Considering that TRECs, in particular, decrease with age in healthy adults, peripheral blood from a young adult, if not from a children, is advised.
    2. Separate peripheral blood mononuclear cells (PBMC) by a standard density gradient separation method.
  2. DNA extraction:
    1. Extract DNA from PBMC using a commercial DNA Blood Mini Kit. Follow the manufacturer’s instructions with the few modifications described below.
      1. Incubate the samples at 70 °C (instead of 56 °C) for 10 min using a shaker-incubator at 1,400 rpm.
      2. Add the elution buffer heated at 70 °C to the column, incubate for 5 min at 70 °C and elute DNA by centrifugation as per manufacturer’s instructions. Determine the extracted DNA concentration by spectrophotometric estimation at 260/280 nm.
  3. Preparation of a plasmid containing the inserts of TREC and KREC signal joints (SJ) and TCRAC reference gene:
    1. Amplify the DNA extracted from PBMC (to obtain the TREC-SJ, KREC-SJ, and TCRAC fragments) with primers specific for TRECs, KRECs and TCRAC (see Table 1).
      NOTE: At the 5’-end, the KREC- and TCRAC-specific primers contain HindIII and SpeI restriction sites (in lower-case in the sequences shown Table 1) with an appropriate number of flanking additional nucleotides (indicated in italic); both features are not present in the canonical KREC and TCRAC sequences.
TRECs forward 5’-AAA GAG GGC AGC CCT CTC CAA GGC-3’
reverse 5’-GGC TGA TCT TGT CTG ACA TTT GC-3’
KRECs forward 5’-CCC aag ctt TCA GCG CCC ATT ACG TTT CT-3’
reverse 5’-CCC aag ctt GTG AGG GAC ACG CAG CC-3’
TCRAC forward 5’-Gac tag tAT GAG ACC GTG ACT TGC CAG-3’
reverse 5’-Gac tag tGC TGT TGT TGA AGG CGT TTG C-3’

Table 1. Primers used for the cloning procedures. At the 5'-end, in lower case are shown nucleotides corresponding to restriction enzyme sites, whereas in italics are shown added flanking nucleotides.

    1. Perform PCR reactions in a final volume of 25 μl, consisting of 1x Buffer II, 1.5 mM MgCl2, dNTP mix (200 µM each), primers at the final concentration of 900 nM, AmpliTaq DNA Polymerase (2.5 U/25 μl), and 100 ng of DNA.
    2. Use the following PCR parameters: first step at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 sec; 60 °C for 30 sec; 72 °C for 30 sec,and finally 1 cycle of 72 °C for 10 min. PCR product lengths should be: 380 bp for TRECs, 166 bp for KRECs, 381 bp for TCRAC.
    3. Insert the PCR product of TREC-SJ in the T-A acceptor site of the pCR2.1-TOPO Vector. Transform the plasmid DNA in XL1-blue chemically competent cells by heat-shock following the protocol provided with the cells. Among the colonies that grow because of ampicillin resistance, identify those carrying the insert, which will appear white because of lost β-galactosidase complementation, and inoculate them into a master dish. Finally, identify the colonies containing the TREC fragment by PCR.
    4. Expand one of the identified colonies and purify the plasmid DNA using a plasmid miniprep kit and follow the manufacturer’s instructions. Digest the plasmid DNA and the TCRAC amplified product with SpeI restriction enzyme and ligate the TCRAC fragment into the SpeI restriction site.
    5. Transform the plasmid DNA in XL1-blue cells and identify the colonies containing the TCRAC fragment by PCR. Expand one of the identified colonies and purify the plasmid DNA using the plasmid miniprep kit.
    6. Digest the plasmid DNA and the KREC amplified product with HindIII and clone the KREC-SJ fragment into the HindIII restriction site. Transform the plasmid DNA in XL1-blue cells and identify the colonies containing the third fragment by PCR.
    7. Verify, by direct sequencing, the presence of the three inserts and the absence of mutations. The map of the final triple-insert plasmid is represented in Figure 1.

Figure 1
Figure 1. Triple-insert plasmid map. Triple-insert plasmid map showing the position of TREC, KREC, TCRAC sequences and restriction enzyme sites. Please click here to view a larger version of this figure.

    1. Expand one of the identified colonies, purify the plasmid DNA using a plasmid midiprep kit. Determine the plasmid DNA concentration by spectrophotometric estimation at 260/280 nm and the DNA quality by gel electrophoresis. Store appropriate aliquots of the plasmid at -80 °C (e.g., 50 μl each).

2. Standard Curve Preparation

NOTE: Prepare all dilutions in 0.1x TE buffer in a place specially designed for containment of DNA carry-over.

  1. Calculate the mass of the plasmid copy numbers of interest (see Table 2), taking into account that the plasmid size is 4,846 bp and that the average mass per bp is 1.096 x 10-21 g/bp, and therefore: mp = (4,846 bp) x (1.096 x 10-21 g/bp) = 5,311.216 x 10-21 g = 5.311 x 10-18 g.
Copy # x 5.311 x 10-18 g Mass of plasmid DNA (g)
1 x 106 5.311 x 10-12
1 x 105 5.311 x 10-13
1 x 104 5.311 x 10-14
1 x 103 5.311 x 10-15
1 x 102 5.311 x 10-16

Table 2. Mass of plasmid needed for each standard curve dilution point.

  1. Calculate the concentrations of plasmid DNA by dividing the needed plasmid masses by the volume (5 μl) to be pipetted into each reaction (see Table 3).
Mass of plasmid DNA (g) ÷ 5 μl Final concentration of plasmid DNA (g/μl)
5.311 x 10-12 1.062 x 10-12
5.311 x 10-13 1.062 x 10-13
5.311 x 10-14 1.062 x 10-14
5.311 x 10-15 1.062 x 10-15
5.311 x 10-16 1.062 x 10-16

Table 3. Calculation of plasmid concentrations needed for each dilution point.

  1. Thaw an aliquot of the plasmid. Linearize 2 μg of the plasmid DNA with XhoI and determine its concentration by spectrophotometric estimation at 260/280 nm.
  2. Prepare a proper dilution of the linearized plasmid DNA in order to achieve a convenient working stock solution to start from (e.g., 100 ng/μl = 0.1 μg/μl = 1 x 10-7 g/μl). Store the remainder of the linearized plasmid DNA at -80 °C.
  3. Perform a convenient number of 1:10 or 1:100 dilutions to bring the plasmid at the more workable concentration of 1 x 10-10 g/μl.
  4. Use the formula C1V1 = C2V2 to calculate the dilution volume (V2 – V1) needed to prepare the first standard curve point of the series (1 x 106 copies, corresponding to 1.062 x 10-12 g/5 μl; see Table 4).
Initial conc. (g/μl)  Plasmid DNA vol (μl)  Diluent vol (μl)  Final Vol. (μl)  Final conc. (g/μl)  Final copy number of plasmid DNA/5μl 
C1 V1 V2-V1 V2 C2
1 x 10-7  5 μl 45 μl 50 μl 1 x 10-8 N/A
1 x 10-8 5 μl 495 μl 500 μl 1 x 10-10 N/A
1 x 10-10 5 μl 465 μl 470 μl 1.062 x 10-12 1 x 106
1.062  x 10-12 50 μl 450 μl 500 μl 1.062 x 10-13 1 x 105
1.062  x 10-13 50 μl 450 μl 500 μl 1.062 x 10-14 1 x 104
1.062  x 10-14 50 μl 450 μl 500 μl 1.062 x 10-15 1 x 103
1.062 x 10-15 50 μl 450 μl 500 μl 1.062 x 10-16 1 x 102

Table 4. Dilution calculations.

  1. Proceed with a regular series of 1:10 dilutions to obtain the remaining standard curve points.
    NOTE: Do not forget to vortex each plasmid dilution briefly before performing the next.
    NOTE: The highest dilution of the standard curve (10 copies/5 μl) must be prepared just before performing the assay, because such a small quantity of plasmid DNA is not stable enough to be stored for future use.
  2. Store the triple-plasmid dilution points at -80 °C in separate tubes until use. The diluted triple-plasmid DNA is highly stable for at least 6 months.

3. DNA Extraction from Target Samples

  1. Separate PBMC from peripheral blood collected into EDTA tubes using the density gradient separation method.
    NOTE: Alternatively, use other appropriate starting material (e.g., sorted lymphocyte subpopulations, whole blood) as target sample.
  2. Extract the DNA from PBMC of target samples as reported in step 1.2.

4. Real-time PCR for Quantification of TRECs and KRECs

  1. Plate preparation and loading:
    1. Arrange a PCR plate including at least two replicates for each samples to be analyzed: standard curve (A→F 1→4), positive control (CTRL+; G1→4) and no-template control (NTC; H 1→4).
      NOTE: Observe a typical scheme in Table 5, but different formats can be created. Remember that TRECs and KRECs will be amplified together in the same wells, distinct from those of TCRAC.
TRECs+KRECsa TCRACb TRECs+KRECs TCRAC TRECs+KRECs TCRAC
1 2 3 4 5 6 7 8 9 10 11 12
A 106 copies 106 copies 106 copies 106 copies 1 1 1 1 9 9 9 9
B 105 copies 105 copies 105 copies 105 copies 2 2 2 2 10 10 10 10
C 104 copies 104 copies 104 copies 104 copies 3 3 3 3 11 11 11 11
D 103 copies 103 copies 103 copies 103 copies 4 4 4 4 12 12 12 12
E 102 copies 102 copies 102 copies 102 copies 5 5 5 5 13 13 13 13
F 10 copies 10 copies 10 copies 10 copies 6 6 6 6 14 14 14 14
G CTRL+ CTRL+ CTRL+ CTRL+ 7 7 7 7 15 15 15 15
H NTC NTC NTC NTC 8 8 8 8 16 16 16 16

Table 5. Sample real-time PCR plate.

    1. Calculate the total number of wells needed (include 1 - 2 extra wells to account for possible pipetting errors) and prepare the master mix for TRECs/KRECs and TCRAC in separate tubes (see Table 6).
      NOTE: The primers and probes specific for TRECs, KRECs and TCRAC are mentioned in Table 7. The primer and probe final concentrations are 900 nM and 200 nM, respectively.
TRECs/KRECs TCRAC
H2O 2 μl H2O 4.75 μl
KRECs for 20 pmol/μl 1.125 μl TCRAC for 20 pmol/μl 1.125 μl
KRECs rev 20 pmol/μl 1.125 μl TCRAC rev 20 pmol/μl 1.125 μl
KRECs probe 10 pmol/μl 0.5 μl TCRAC probe 10 pmol/μl 0.5 μl
TRECs for 20 pmol/μl 1.125 μl 2x TaqMan Universal PCR Master Mix 12.5 μl
TRECs rev 20 pmol/μl 1.125 μl
TRECs probe 10 pmol/μl 0.5 μl
2x TaqMan Universal PCR Master Mix  12.5 μl

Table 6. Volume of reagents needed for the indicated wells.

TRECs forward 5’-CAC ATC CCT TTC AAC CAT GCT-3’
reverse 5’-TGC AGG TGC CTA TGC ATC A-3’
probe 5’-FAM-ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT-TAMRA-3’
KRECs forward 5’-TCC CTT AGT GGC ATT ATT TGT ATC ACT-3
reverse 5’-AGG AGC CAG CTC TTA CCC TAG AGT-3’
probe 5’-HEX-TCT GCA CGG GCA GCA GGT TGG-TAMRA-3
TCRAC forward 5’-TGG CCT AAC CCT GAT CCT CTT-3’
reverse 5’-GGA TTT AGA GTC TCT CAG CTG GTA CAC-3
probe 5’-FAM-TCC CAC AGA TAT CCA GAA CCC TGA CCC-TAMRA-3’

Table 7. Sequence of primer and probes for the real-time PCR assay.

    1. Add 20 µl of each mix (TRECs/KRECs and TCRAC). Before leaving the reagent preparation room, seal the reaction plate with an optical adhesive cover.
    2. In a nucleic acid extraction room, lift the adhesive cover and add 5 µl of genomic DNA sample (400 - 500 ng) to the wells. Add 5 µl of genomic DNA (i.e., prepared from PBMC obtained from umbilical cord blood) to the CTRL+ wells.
      NOTE: As an alternative to umbilical cord blood, use DNA from the same known, positive peripheral blood sample or pool of samples, or prepare an “artificial” positive standard by mixing a determined amount of triple-insert plasmid with genomic DNA from TREC- and KREC-negative cell lines.
    3. Add 5 µl of water to the NTC wells. Seal the reaction plate again with the optical adhesive cover.
    4. Move to a place ensuring containment of plasmid DNA carry-over; thaw each dilution point of the plasmid DNA standard curve only before use and prepare the highest dilution (10 copies/5 µl). Lift up the adhesive cover only from A→H 1→4 wells and add 5 µl of each point dilution of plasmid DNA standard curve. Seal the adhesive cover again.
    5. Verify the absence of bubbles on the bottom of the wells, thus ensuring that the reagents are positioned at the bottom.
    6. Run the assay on a Real-time PCR system. The standard protocol consists of first step at 50 °C for 2 min, an initial heating at 95 °C for 10 min, followed by 45 cycles of denaturation at 95 °C for 15 sec, and a combined primer/probe annealing and elongation at 60 °C for 1 min.
    7. Save the data at the end of PCR program.
      NOTE: To avoid DNA cross-contamination, remember: to follow the usual good laboratory practice recommendations for quantitative PCR when setting up the real time PCR assay: use separate areas/rooms for nucleic acid extraction, reagent preparation, plasmid manipulation, amplification reaction; use separate pipette sets; change gloves/coats as appropriate.
  1. Results and calculation:
    NOTE: The following steps are based on our experience using the software provided with the real-time PCR instrument mentioned in the Materials Table, but, in general, they should apply to other real-time PCR analysis platforms and softwares. Keep in mind that, even if using the same software, usually there is more than one way to execute the required commands (e.g., icons, shortcuts).
    1. Open the saved result file in the software and click on the “Results” tab. On top of the window, click on “Analysis” menu and select “Analysis settings”. Let the software determine the threshold automatically by selecting “All” detectors and “Auto Ct” (Ct = threshold cycle. Let the software set “Automatic Baseline” for background elimination by default.
    2. Click on the tab named "Amplification Plot" and, at the rightmost part of the window, select one of the three "detectors" in the corresponding drop-down menu (e.g., start with TRECs). Just below, select "Manual Ct" to manually set a threshold; go to the lower part of the window and select the wells corresponding to the standard curve dilution points of the chosen detector to show the amplification plots. To do this just click and drag the mouse over the corresponding cells of the table.
      1. To adjust the threshold manually, drag the red threshold line up and down, and then click "Analyze" to reanalyze results. To check how setting the threshold affects the results, select the “Report” tab, and see the resulting Ct of the respective standard curve dilution points. When moving the threshold, try to comply with the following recommendations to get an optimal placement.
      2. Go back to the "Amplification Plot" tab and verify that the threshold is in a region of exponential amplification sufficiently above the background noise but below the plateau phase. If the amplification plot is not shown in logarithmic scale, right-click on the plot to recall the “Graph Settings” and set post-run Y-axis setting as "log", set the threshold half-way in the linear part of the plot, and observe the amplification curves approximately parallel to each other.
      3. Click on the “Report” tab to see the Ct results. Ensure that the threshold placement produced results that maximize the precision of the two replicates of each standard curve dilution points.
      4. Check that the threshold is placed at the point which best reflects the extreme orders of magnitude of the standard curve dilution points (optimal sensitivity). Repeat step 4.2.2 and remaining substeps for the remaining two detectors (KRECs and TCRAC).
      5. Go to the Report tab, drag the mouse again in the table at the lower portion of the window to select the cells corresponding to the wells of the standard curve for all detectors (TRECs, KRECs, TCRAC). Verify that the resulting Ct of the three targets is very similar at the same dilution points (e.g., difference not more than 0.5 Ct). Readjust thresholds if needed and re-check.
        NOTE: Because the triple-insert plasmid contains a single-copy of each target and therefore the amplification ratio should theoretically be close to 1:1:1. In some cases it may be necessary to manually adjust also the baseline for one or more of the detectors to get better results. Just recall the “Analysis settings” window, select the detector for which the adjustment is needed, then set “Manual Baseline”, and insert custom values for the Start and End Cycles (usually 3 to 15). Then click “OK & Reanalyze” and recheck previous points.
    3. Accept the experimental session only after verifying the following:
      1. Click on the “Report” tab, go to the lower portion of the window, select NTC wells and check that the corresponding Ct is “Undet” (i.e., no amplification is present in NTC wells).
      2. Select the “Standard Curve” tab and look to the right of the plot window; select detectors from the drop-down menu and see whether the reported standard curve slope ranges between -3.55 and -3.32 (corresponding to PCR efficiencies of 91 - 100%)
      3. Make sure that the coefficient of determination (R2) is higher than 0.998 (Figure 2), by reading its value right below the slope and intercept (in the same “Standard Curve” tab, after selecting each detector).
        NOTE: Pay attention to the extreme dilution points because their misalignment may affect the slope more easily (they have a high “leverage” effect on the regression line). In particular, keep in mind that the highest plasmid dilution may degrade sooner than expected. However, whenever possible it is useful not to discard them, because a rational approach may be to consider 100 as the limit of quantitative detection: in other words, for samples between 10 and 100, the result may be reported as <100 or “positive, but not quantifiable”, while if outside the curve range (<10) it may be reported as 0 or “undetectable”.
        NOTE: It may be useful to keep an archive of the Ct values of previous standard curve dilutions, in order to calculate an average value for each dilution point to be kept as a sort of optimal “reference” range or internal quality check for future experiments (e.g., calculate mean and SD to build Shewhart control charts). Analogously, it may be helpful to keep an archive of the past Ct of the positive control.

Figure 2
Figure 2. Standard curves for TRECs, KRECs, and TCRAC. Plots of the standard curve points and log-regression line estimates for TRECs (A), KRECs (B), and TCRAC (C) are built to verify compliance with the ideal exponential amplification rate (slope = 3.32) that would correspond to an efficiency of 100%. Ct: threshold cycle; R2: regression coefficient of determination. Please click here to view a larger version of this figure.

      1. Click on the “Report” tab and verify that the Ct of the positive control (found in the corresponding cells of the table under the chart) is consistent with the results of the previous assays on the same known positive control.
        NOTE: The “Report” tab shows the amount of TRECs, KRECs and TCRAC of the samples being tested that the software has calculated by interpolation from the respective standard curve, using the Ct values obtained after the threshold and baseline have been properly set (a new analysis with a new threshold/baseline would change these results). To see where the interpolation takes place on the standard curve, select the “Standard Curve” tab, then select the desired wells, and look for the black “X” appearing on the regression line. Their y-axis value is the interpolated quantity. If using always the same positive control, appropriate reference ranges and/or quality control charts can be built, based on previous values determined on the positive control.
    1. Click on “File” menu, “Save”, and then “Export” to a .csv file to export the quantities of all wells in a text file containing comma separated values.
    2. Import the.csv file in a spreadsheet software and calculate the number of TRECs or KRECs per 106 PBMC by setting the following formula appropriately: [(mean quantity of TRECs or KRECs) / (mean quantity of TCRAC/2)] x 106
      NOTE: The mean quantity of TCRAC is divided by 2 because in each cell there are two TCRAC gene copies, e.g., one for each chromosome.
      NOTE: The consistency of the final number of TRECs and KRECs of positive control may be regarded, but keep in mind that values will not perfectly match because of the added variability of the standard curve dilution points. In case of gross divergence, the experiment may need to be repeated. Again, control charts may be built to set an appropriate reference range.
    3. (optional, but recommended) If the results of the complete blood count are available, calculate the TRECs or KRECs per ml of blood using the following formula:
      TRECs or KRECs per 1 x 106) x (lymphocyte + monocyte count in 1 ml of blood) / 106 = copies/ml.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

The assay was performed in a representative sample of 87 healthy controls: 42 children aged 0 - 17 (male/females: 25/17) and 45 adults aged 24 - 60 (males/females: 29/16). Results were obtained as TRECs and KRECs per 106 PBMC, and then the TRECs and KRECs per ml of blood were calculated.

The number of TRECs decreases with age due to thymic involution,4 in particular in a very sharp fashion from 0 to 3 - 4 years. In adults, the TREC number also depends on gender because it decreases more rapidly in men than in women.5 This may create problems in setting appropriate reference ranges, which should be differentiated on the basis of the age and possibly gender, if a very precise estimation of normality is needed.

Figure 3
Figure 3. TREC quantification in healthy donors. The amount of TRECs was determined as TRECs/106 cells in healthy children (A) and adults (B) and then calculated as TRECs/ml in the same subjects (C, D). Clear circles: females; filled circles: males. Lines were obtained by linear regression using log-transformed data. In children, two regression lines were fitted to better represent the variable rate of TREC decrease with age. In adults, dashed lines represent the trend of decrease with age of TRECs seen in females, which is slower than in males (continuous line). Please click here to view a larger version of this figure.

The number of KRECs decreases with the age with a pattern similar to TRECs only in children, whereas in the adults the bone marrow output is fairly stable throughout life and does not depend on gender.

Figure 4
Figure 4: KREC quantification in healthy donors. The amount of KRECs was determined as KRECs/106 cells in healthy children (A) and adults (B) and then calculated as KRECs/ml in the same subjects (C, D). Clear circles: females; filled circles: males. Lines were obtained by linear regression using log-transformed data. In children, two regression lines were fitted to better represent the variable rate of KREC decrease with age. Please click here to view a larger version of this figure.

For representative purposes, simple log-linear regression models were fitted to depict the pattern of TREC/KREC decrease with age, but more refined non-linear models may be fitted in an attempt to better predict the seemingly exponential KREC/TREC decrease with age.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

TREC and KREC quantification can be considered a good estimate of recent thymic and bone marrow output provided that some caveats are taken into account. Even though an absolute quantification method employing standard curve requires more reagents and more space on the real-time PCR reaction plate, it ensures highly accurate quantitative results because unknown sample quantities are interpolated from standard curves built upon known amounts of starting material. Moreover this method is better fitted to detect low amount of targets. From the methodological point of view, a critical point is that the frozen plasmid dilutions corresponding to the standard curve points may degrade sooner than expected. This requires that new dilutions from the originally stored plasmid need to be prepared before each experimental procedure, in particular the most dilute ones. In the final calculations, a non-perfect equivalence between lymphocyte plus monocyte count as an estimate of the PBMC quantity may add some bias in the conversion between values expressed per 106 and values expressed per ml of blood. An improvement can be made to determine the amount of two targets (TRECs and KRECs) from a known amount of DNA extracted directly from whole blood, thus eliminating the need of the monocyte plus lymphocyte counts.14 In this specific case, a reference gene is not strictly necessary to perform the quantification, but may be used as an additional DNA quality and quantity check.

The result interpretation can be affected by some issues. First of all, it should be taken into account that reference ranges change with gender and age, determining marked differences between children and adults. Furthermore, in case of certain immune deficiencies or autoimmune syndromes, a homeostatic peripheral replication of existing memory cells can be present, which dilutes TREC/KREC content and lowers the result of the assay when expressed only per 106 lymphocytes. This may lead to the erroneous conclusion that the thymic/bone marrow output is lower than it actually is. Therefore, it is advisable to always estimate lymphocyte neoproduction by also calculating TRECs/KRECs per ml of blood, which makes results independent of the proliferation rate of memory cells. Third, whatever is the unit of measure, the test result may lead to biased overestimates, due to persistence of some long-lived naïve lymphocytes that still bear TRECs or KRECs. Therefore, those who are interested in the best possible estimate of “true” lymphocyte neoproduction can take advantage of some more complicated mathematical models that also takes into account the lymphocyte apoptosis rate.15

An improvement of assay sensitivity to enhance its use is to perform TRECs and KRECs quantification starting from a limited amount of capillary whole blood spotted on Guthrie card filter paper. This modified version of the assay can be applied with success to the newborn screening of congenital immune deficiencies affecting lymphocyte production,12 and was proved beneficial in terms of cost-efficacy. This simplified version of assay also paves the way to new potential applications, especially considering the high number of potent immune modulating drugs that have been developed in the last few years. However, the “classical” TREC/KREC assay herein described has been already applied with success as a routine test in the follow up of children with severe congenital immune deficiencies following hematopoietic stem cell transplantation,4 or for the monitoring of the therapy outcome of autoimmune diseases and acquired immune deficiencies.6-9,11

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors have no acknowledgements.

Materials

Name Company Catalog Number Comments
Histopaque-1077 Sigma Aldrich SRL 10771-500 ML density gradient separation method
QIAamp DNA Blood Mini Kit (250) QIAGEN 51106 DNA extraction
Unmodified DNA Oligonucleotides HPSF 0.01 mmol Eurofins MWG Operon/Carlo Erba Reagents S.r.l  Resuspend the lyophilized product to 100 pmol/µl
AmpliTaq DNA Polymerase: including 10x Buffer II and 25 mM MgCl2 Applied Biosystems/Life-Technologies N8080156
GeneAmp dNTP Blend (100 mM) Applied Biosystems/Life-Technologies N8080261
TOPO TA Cloning Kit for Subcloning Invitrogen/Life-Technologies K4500-01
XL1-Blue Subcloning Grade Competent Cells Stratagene 200130
PureYield Plasmid Miniprep System Promega A1223
SpeI 500U New England Biolabs R0133S
HindIII-HF 10,000 U New England Biolabs R3104S
PureYield Plasmid Midiprep System Promega A2492
XhoI 5,000 U New England Biolabs R0146S
TRIS Utrapure Sigma Aldrich SRL T1503
EDTA Sigma Aldrich SRL E5134
TE buffer (1 mM TRIS and 0.1 mM EDTA)
TaqMan Universal PCR Master Mix Applied Biosystems/Life-Technologies 4364338
Dual labeled probes HPLC 0.01 mmol Eurofins MWG Operon/Carlo Erba Reagents S.r.l  Resuspend the lyophilized product to 100 pmol/µl
NanoDrop 2000c spectrophotometer ThermoFisher
Applied Biosystems 2720 Thermal Cycler Applied Biosystems/Life-Technologies 4359659
Fast 7500 Real-Time PCR system Applied Biosystems/Life-Technologies
SDS Sequence Detection Software 1.4 Applied Biosystems/Life-Technologies

DOWNLOAD MATERIALS LIST

References

  1. Douek, D. C., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396, (6712), 690-695 (1998).
  2. Zelm, M. C., Szczepanski, T., van der Burg, M., van Dongen, J. J. M. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J. Exp. Med. 204, (3), 645-655 (2007).
  3. Fronkova, E., et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant. 42, (3), 187-196 (2008).
  4. Sottini, A., et al. Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clin. Immunol. 136, (2), 217-227 (2010).
  5. Serana, F., et al. Thymic and bone marrow output in patients with common variable immunodeficiency. J. Clin. Immunol. 31, (4), 540-549 (2011).
  6. Zanotti, C., et al. Opposite effects of interferon-β on new B and T cell release from production sites in sclerosis. J. Neuroimmunol. 240-241, 147-150 (2011).
  7. Zanotti, C., et al. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clin. Immunol. 145, (1), 19-26 (2012).
  8. Sottini, A., et al. Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient. PLoS One. 7, e34493 (2012).
  9. Quiros-Roldan, E., et al. Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients. J. Transl. Med. 10, 94 (2012).
  10. Mensen, A., et al. Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. J. Transl. Med. 11, 188 (2013).
  11. Serana, F., et al. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J. Immunol. 185, (12), 7713-7722 (2010).
  12. Borte, S., et al. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 119, (11), 2552-2555 (2012).
  13. Baker, M. W., et al. Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep. 125, (2), 88-95 (2010).
  14. Lorenzi, A. R., et al. Determination of thymic function directly from peripheral blood: a validated modification to an established method. J. Immunol. Meth. 339, (2), 185-194 (2008).
  15. De Boer, R. J., Perelson, A. S. Quantifying T lymphocyte turnover. J. Theor. Biol. 327, 45-87 (2013).

Comments

0 Comments


    Post a Question / Comment / Request

    You must be signed in to post a comment. Please or create an account.

    Usage Statistics